Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 11/20 | 0.66 |
| ▸ | BACE1 | P56817 | 2/20 | 0.66 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.66 |
| ▸ | PTGES | O14684 | 1/20 | 0.66 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.66 |
| ▸ | CNR2 | P34972 | 2/20 | 0.61 |
| ▸ | CNR1 | P21554 | 1/20 | 0.61 |
| ▸ | BMP1 | P13497 | 1/20 | 0.60 |
| ▸ | RORC | P51449 | 1/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9287153 | 0.90 | RORC (0.68) | TAS2R14BACE1CXCR3PTGESTAS2R8 | |
| SCHEMBL6323932 | 0.87 | TAS2R14 (0.62) | TAS2R14BACE1CXCR3PTGESTAS2R8 | |
| SCHEMBL28729777 | 0.86 | TAS2R14 (0.80) | TAS2R14CXCR3PTGESTAS2R8CNR2 | |
| SCHEMBL6323674 | 0.86 | MMP9 (0.60) | TAS2R14BACE1CXCR3PTGESTAS2R8 | |
| SCHEMBL6321716 | 0.85 | TAS2R14 (0.61) | TAS2R14BACE1CXCR3PTGESTAS2R8 | |
| SCHEMBL6323899 | 0.83 | TAS2R14 (0.58) | TAS2R14BACE1CXCR3PTGESTAS2R8 | |
| SCHEMBL28738327 | 0.83 | SPPL2A (0.60) | TAS2R14CXCR3PTGESTAS2R8KEAP1 | |
| SCHEMBL28628356 | 0.83 | SPPL2A (0.60) | TAS2R14CXCR3PTGESTAS2R8KEAP1 | |
| SCHEMBL28628359 | 0.83 | SPPL2A (0.60) | TAS2R14CXCR3PTGESTAS2R8KEAP1 | |
| SCHEMBL28628358 | 0.83 | SPPL2A (0.60) | TAS2R14CXCR3PTGESTAS2R8KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014840-A1 | Thiol sulfonamide metalloprotease inhibitors | PHARMACIA CORPORATION | 2005-01-20 | — | — | US | disclosed |
| US-6747027-B1 | SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 | PHARMACIA CORPORATION | 2004-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014840-A1 | Thiol sulfonamide metalloprotease inhibitors | MMP12, MMP13, MMP3 | TAS2R14 1996/4885BACE1 387/4885CXCR3 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.